Dr. Amer H. Zureikat, MD

Dr. Zureikat practices at UPMC Presbyterian in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Dr. Zureikat's NPI, 1063673465, was assigned on June 19, 2008. Dr. Zureikat holds Pennsylvania license MD434314.

Dr. Zureikat's primary practice is UPMC Presbyterian, at 200 Lothrop Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 647-2345.

Dr. Zureikat's primary practice is UPMC Presbyterian in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Dr. Zureikat is also affiliated with Select Specialty Hospital - Pittsburgh / UPMC. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Dr. Zureikat to 5 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zureikat practices, 7 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Zureikat's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Zureikat is licensed in Pennsylvania.

CMS data shows 101 Medicare services from Dr. Zureikat across 4 procedure codes in 2024, for 98 Medicare patients. Medicare paid $31,732 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 98 Medicare patients who saw Dr. Zureikat in 2024. The largest group is 65 to 74, with 55 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zureikat's median patient age at 73, with 49% women.

In 2024, Dr. Zureikat wrote 357 Medicare Part D claims for 86 patients. 54% of them were for generic drugs. CMS names the drug for 302 of them, across 3 drugs with 11 or more claims each, at $723,047 in total drug cost. In 2023, CMS named 429 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Zureikat for performance year 2024, reported as part of a group. Dr. Zureikat accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zureikat as offering telehealth.

Dmand AI links 293 papers to Dr. Zureikat, published from 2010 to 2025. 2020 was the busiest year, with 33. The most frequent topics are Pancreatic Neoplasms, Pancreaticoduodenectomy and Pancreatectomy. Dr. Zureikat has published most often in Ann Surg Oncol. Dr. Zureikat's most frequent co-authors are Melissa Ellen Hogg, MD, David Lawrence Bartlett, MD and Herbert John Zeh, MD.

Dmand AI links Dr. Zureikat to 1 clinical trial. 1 is still active or recruiting.

CMS Open Payments shows 44 general payments to Dr. Zureikat from 6 drug and device companies from 2017 to 2025. Education make up the largest share, 32% of the total. Intuitive Surgical, Inc. paid the most, $6,208.